UNIVERSITY OF EXETER

Researchers at the University of Exeter and Serac Healthcare Ltd are developing a new molecular imaging marker, ^99mTc-maraciclatide, to detect interstitial lung disease progression. The PREDICT-ILD study aims to evaluate its potential for early diagnosis, which could improve patient outcomes and aid in the development of new therapies.

Researchers at the University of Exeter and Serac Healthcare Ltd are evaluating ^99mTc-maraciclatide, a novel imaging agent, in the PREDICT-ILD study to predict interstitial lung disease progression. The study aims to improve early detection and treatment, supported by the Wellcome Trust and NIHR Exeter Biomedical Research Centre.

Serac Healthcare and the University of Exeter announce the first patient scan using ^99mTc-maraciclatide in the PREDICT-ILD Phase II study, aiming to evaluate its efficacy as an imaging marker for ILD prognostication. The study, led by Professors Chris Scotton and Giles Dixon, is funded by the Wellcome Trust and involves 69 participants, with 15 in the sub-study. The primary endpoint is to compare ^99mTc-maraciclatide uptake between IPF, non-IPF fibrosing-ILD, and healthy controls.

Serac Healthcare and University of Exeter start Phase II study on 99mTc-maraciclatide, a SPECT imaging agent for ILD prognostication. PREDICT-ILD aims to assess CT effectiveness in ILD progression detection, with a sub-study evaluating 99mTc-maraciclatide. Recruitment ongoing at three NHS sites, led by Professors Scotton and Dixon, funded by Wellcome Trust. Sub-study to compare 99mTc-maraciclatide uptake between IPF, non-IPF fibrosing-ILD, and healthy controls, aiming to predict disease progression.

CUHK fosters global research collaborations to enhance its international profile and advance research. Key partnerships include Baylor College of Medicine for medical genetics, ETH Zurich for healthcare innovation, Imperial College London for healthcare solutions, LMU Munich for medical research, The University of Manchester for diverse research areas, The University of Queensland for health engineering, The University of Sydney for various research fields, University of Exeter for environmental sustainability, University of Oxford for neuroscience and public health, and University of Southampton for stem cell research.

A UCL study found a single ketamine dose reduced heavy drinkers' alcohol cravings and intake over nine months by disrupting drinking-related memories. Experts call for further research, noting ketamine's potential in addiction treatment despite its risks and legal status as a Class-B drug.